7 research outputs found
LPS-stimulated production of TNFα (panel A) and IL-6 from whole blood from healthy control subjects (n = 11, black line) and patients with CHF (n = 42, gray line).
<p>* <i>vs.</i> unstimulated control (0 ng/mL LPS); § <i>vs.</i> 0.1 ng/mL LPS; †<i>vs.</i> 1 ng/mL LPS; # <i>vs.</i> 10 ng/mL LPS. One symbol denotes p<0.05, two symbols p<0.01, three symbols p<0.001, four symbols p<0.0001.</p
Baseline data for control subjects and patients with CHF.
<p>Baseline data for control subjects and patients with CHF.</p
Distribution of leukocytes (panel A) and their subsets (panels B and C) in healthy control subjects (n = 20) and patients with CHF (n = 75).
<p>Distribution of leukocytes (panel A) and their subsets (panels B and C) in healthy control subjects (n = 20) and patients with CHF (n = 75).</p
Distribution of lymphocyte subsets in healthy control subjects (n = 20) and patients with CHF (n = 75).
<p>Distribution of lymphocyte subsets in healthy control subjects (n = 20) and patients with CHF (n = 75).</p
Baseline marker of immune activation and cytokines.
<p>Baseline marker of immune activation and cytokines.</p
Effect of β-blockers.
†<p>p<0.05 vs. control; ††p<0.01 vs. control; †††p<0.001 vs. control; ††††p<0.0001 vs. control * p<0.05 vs. patients on a beta-blocker; ** p<0.01 vs. patients on a beta-blocker; *** p<0.001 vs. patients on a beta-blocker; **** p<0.0001 vs. patients on a beta-blocker. # p-values were calculated using the analysis of variance (ANOVA) method of testing.</p